Päivi H Salonen1,2, Juha H Salonen3, Hanna Säilä4, Mika Helminen5,6, Miika Linna7, Markku J Kauppi8,9. 1. Faculty of Medicine and Life Science, Tampere University, Tampere, Finland. paivi.salonen@tuni.fi. 2. Päijät-Häme Joint Authority for Health and Wellbeing, Terveystie 4, 15870, Lahti, Hollola, Finland. paivi.salonen@tuni.fi. 3. Department of Infectious Diseases, Vaasa Central Hospital, Vaasa, Finland. 4. Orton Research Institute, Orton Foundation, Helsinki, Finland. 5. Research, Development and Innovation Centre, Tampere University Hospital, Tampere, Finland. 6. Faculty of Social Sciences, Health Sciences, Tampere University, Tampere, Finland. 7. Aalto University, Helsinki, Finland. 8. Faculty of Medicine and Life Science, Tampere University, Tampere, Finland. 9. Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.
Abstract
OBJECTIVES: Children with juvenile idiopathic arthritis (JIA) may be predisposed to serious pneumonia due to modern disease-modifying anti-rheumatic treatment. In this nationwide retrospective study with clinical data, we describe the pneumonia episodes among children with JIA. METHODS: Patients under 18 years of age with JIA and pneumonia during 1998-2014 were identified in the National Hospital Discharge Register in Finland. Each individual patient record was reviewed, and detailed data on patients with JIA and pneumonia were retrieved, recorded, and analyzed. If the patient was hospitalized or received intravenous antibiotics, the pneumonia was considered serious. RESULTS: There were 157 episodes of pneumonia among 140 children with JIA; 111 episodes (71%) were serious (80% in 1998-2006 and 66% in 2007-2014). The mean age of the patients was 9 years. Forty-eight percent had active JIA and 46% had comorbidities. Disease-modifying anti-rheumatic drugs (DMARD) were used at the time of 135 episodes (86%): methotrexate (MTX) by 62% and biologic DMARDs (bDMARD) by 30%. There was no significant difference in the use of bDMARDs, MTX and glucocorticoids between the patient groups with serious and non-serious pneumonia episodes. During six of the episodes, intensive care was needed. Two patients (1.3%) died, the remaining ones recovered fully. CONCLUSIONS: Although the incidence of pneumonia and the use of immunosuppressive treatment among children with JIA increased from 1998 to 2014, the proportion of serious pneumonias in these patients decreased. There was no significant difference in the use of anti-rheumatic medication between patients with serious and non-serious pneumonia.Key Points• The incidence of serious pneumonias decreased from 1998 to 2014 among children with juvenile idiopathic arthritis (JIA).• There was no significant difference in the use of the disease-modifying anti-rheumatic medication between JIA patients with serious and non-serious pneumonias.• Active JIA, comorbidities, and combination medication were associated with nearly half of the pneumonias.
OBJECTIVES:Children with juvenile idiopathic arthritis (JIA) may be predisposed to serious pneumonia due to modern disease-modifying anti-rheumatic treatment. In this nationwide retrospective study with clinical data, we describe the pneumonia episodes among children with JIA. METHODS:Patients under 18 years of age with JIA and pneumonia during 1998-2014 were identified in the National Hospital Discharge Register in Finland. Each individual patient record was reviewed, and detailed data on patients with JIA and pneumonia were retrieved, recorded, and analyzed. If the patient was hospitalized or received intravenous antibiotics, the pneumonia was considered serious. RESULTS: There were 157 episodes of pneumonia among 140 children with JIA; 111 episodes (71%) were serious (80% in 1998-2006 and 66% in 2007-2014). The mean age of the patients was 9 years. Forty-eight percent had active JIA and 46% had comorbidities. Disease-modifying anti-rheumatic drugs (DMARD) were used at the time of 135 episodes (86%): methotrexate (MTX) by 62% and biologic DMARDs (bDMARD) by 30%. There was no significant difference in the use of bDMARDs, MTX and glucocorticoids between the patient groups with serious and non-serious pneumonia episodes. During six of the episodes, intensive care was needed. Two patients (1.3%) died, the remaining ones recovered fully. CONCLUSIONS: Although the incidence of pneumonia and the use of immunosuppressive treatment among children with JIA increased from 1998 to 2014, the proportion of serious pneumonias in these patients decreased. There was no significant difference in the use of anti-rheumatic medication between patients with serious and non-serious pneumonia.Key Points• The incidence of serious pneumonias decreased from 1998 to 2014 among children with juvenile idiopathic arthritis (JIA).• There was no significant difference in the use of the disease-modifying anti-rheumatic medication between JIApatients with serious and non-serious pneumonias.• Active JIA, comorbidities, and combination medication were associated with nearly half of the pneumonias.
Authors: John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson Journal: Clin Infect Dis Date: 2011-08-31 Impact factor: 9.079
Authors: Heini Pohjankoski; Katariina Latva; Hannu Kautiainen; Hanna Säilä; Timo Klaukka; Lauri Virta; Kari Puolakka; Timo Pohjolainen; Anneli Savolainen Journal: Clin Exp Rheumatol Date: 2011-10-31 Impact factor: 4.473
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Sarah Ringold; Shannon Grant; Charmaine Girdish; Carol A Wallace; Sean D Sullivan Journal: Arthritis Care Res (Hoboken) Date: 2013-11 Impact factor: 4.794
Authors: J Anthony G Scott; Chizoba Wonodi; Jennifer C Moïsi; Maria Deloria-Knoll; Andrea N DeLuca; Ruth A Karron; Niranjan Bhat; David R Murdoch; Jane Crawley; Orin S Levine; Katherine L O'Brien; Daniel R Feikin Journal: Clin Infect Dis Date: 2012-04 Impact factor: 9.079
Authors: Arto A Palmu; Hanna Rinta-Kokko; Hanna Nohynek; J Pekka Nuorti; Terhi M Kilpi; Jukka Jokinen Journal: PLoS One Date: 2017-03-01 Impact factor: 3.240
Authors: Timothy Beukelman; Fenglong Xie; John W Baddley; Lang Chen; Melissa L Mannion; Kenneth G Saag; Jie Zhang; Jeffrey R Curtis Journal: Arthritis Res Ther Date: 2016-09-22 Impact factor: 5.156